Navigation Links
AEterna Zentaris Announces First Patient Dosing for Safety Trial of Phase 3 Program with Cetrorelix in Benign Prostatic Hyperplasia
Date:5/14/2008

QUEBEC CITY, May 14 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today reported dosing has commenced in the safety study of the Company's Phase 3 program with cetrorelix in benign prostatic hyperplasia (BPH).

Cetrorelix, a novel investigational luteinizing hormone-releasing hormone (LHRH) antagonist, is the Company's flagship product candidate. This 500-patient safety trial is the third of three Phase 3 studies - planned to enroll a total of 1,500 patients - to define the role of cetrorelix in the treatment of BPH, a non-cancerous enlargement of the prostate affecting millions of men.

"With this additional study, all three trials of our Phase 3 program are now in full gear. This milestone brings us one step closer to our goal of providing a novel, safe and efficient therapeutic approach to the millions of men suffering from BPH," said Paul Blake, M.D., Senior Vice President and Chief Medical Officer at AEterna Zentaris.

The safety study titled, "Cetrorelix pamoate in patients with symptomatic BPH: an open labeled safety and efficacy assessment study", will involve approximately 500 patients in North America and Europe, and will assess an intermittent dosage regimen of cetrorelix pamoate as a potential safe and tolerable treatment providing prolonged improvement in BPH-related signs and symptoms. Patients will receive cetrorelix pamoate by intra-muscular (IM) injection at weeks 0 and 2, and will be followed up to week 26. The main endpoint is the incidence of possibly drug-related adverse events.

About Cetrorelix

Cetrorelix is part of AEterna Zentaris' LHRH antagonist therapeutic approach that has dem
'/>"/>

SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. AEterna Zentaris to Announce Third Quarter 2007 Financial and Operating Results on November 7, 2007
2. Amarin Announces Private Placement for up to $60 Million
3. NightHawk Radiology Holdings, Inc. Announces Dutch Tender Offer for Its Common Stock
4. Simcere Pharmaceutical Group Announces SFDA Approval of First-to-Market Generic Biapenem Injection Anxin
5. Veria Announces Acquisition of Massage Envy Ltd.
6. TOFUTTI Announces First Quarter Results
7. Natural Alternatives International, Inc. Announces Third Quarter Results
8. eDiets.com(R) Announces Q1 2008 Results
9. Boston Scientific Announces FDA Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death
10. United American Healthcare Corporation Announces Fiscal 2008 Third Quarter Results
11. The Blue Foundation for a Healthy Florida Announces $8 Million Initiative to Address Childhood Obesity
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Celebration can quickly turn to tragedy if popular turkey ... Over the last decade, more than 141 serious fires ... turkey fryers, according to the U.S. Consumer Product Safety ... who tried to deep fry the turkey indoors, which ... Arthur Sanford, a burn surgeon at Loyola University Health ...
(Date:11/28/2014)... (PRWEB) November 28, 2014 Not only ... create products free of petroleum, parabens and other cancer-causing ... that fund research, education and awareness programs that help ... staff and owners have raised an incredible, record-breaking contribution ... the Cure, sales of the Sweet Red Rose Whip ...
(Date:11/28/2014)... Angeles, CA (PRWEB) November 28, 2014 ... online, reported during the hugely popular, 2014 ... the antismoking organization Truth launched ground-breaking celebrity centered ... 18-49. The MTV viewership figures were estimated by ... Truth antismoking ads placed the spotlight on celebrities ...
(Date:11/28/2014)... 28, 2014 A newly released article ... overview of the influenza virus that will soon be spreading ... , The article begins with a brief explanation of what ... It reminds families that children under the age of 5, ... chronic diseases, such as heart and lung diseases, asthma, or ...
(Date:11/28/2014)... November 28, 2014 Patten Pecans, based ... grown. With those passions driving them, they've added a ... Having tried other pecans oils, they've found this ... to be exceptionally flavorful, retaining the buttery pecan notes ... nutritional benefits found in pecans nuts is ...
Breaking Medicine News(10 mins):Health News:Turkey Fryer Mishaps Can Cause Serious Burns 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 2Health News:Éminence Organic Skin Care Donates Record-breaking $30,000 to Breast Cancer Research 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 2Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 3Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 4Health News:Freedom Laser Therapy Applauds American Legacy’s Creative Advertising Targeting Celebrity Smokers 5Health News:How Flu Vaccines Can Impact Families Is Discussed in New Article from Community Health Center of Snohomish County 2Health News:Patten Pecans Goes Local with Nutritious Georgia Pecan Oil 2
... Memory,Pharmaceuticals Corp. (Nasdaq: MEMY ) today announced ... composition of matter patent,protection for a series of ... R4996/MEM 63908, which are both being developed,in partnership ... such as,Alzheimer,s disease and cognitive impairment associated with ...
... people worship felines,like pharos; dog people talk to hounds ... really are different -- in marital status, economic,standing and ... that there are some interesting differences,between cat owners and ... American Veterinary Medical Association (AVMA). "Our surveys show,that single ...
... in the market for specialty needles is determined by growing demand ... is projected to reach $3.7 billion by the year 2015. ... ... The market for disposable medical products such as syringes, disposable needles, ...
... solely as disease agents -- now are being used ... these so-called oncolytic viruses stem from their potential to ... a way of controlling the viruses behind potential cancer ... microRNAs to restrict them to specific tissues. The microRNAs ...
... Consulting Service is quickly becoming the nation’s leader in ... in 2008 and has already achieved six Joint Commission certifications ... Consulting Service assures agencies understand and meet the healthcare standards ... ...
... association says cooling body, checking arteries lowers risk of further ... heart beating again is only the first step in saving ... shows. , An advisory, published in the Oct. 23 issue ... more quickly after resuscitation or risk the losing the patient ...
Cached Medicine News:Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 2Health News:Memory Pharmaceuticals Announces Issuance of Key U.S. Patent for R3487/MEM 3454 and R4996/MEM 63908 3Health News:Cat People vs. Dog People ... They Really are Different 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 2Health News:Special Purpose Needles Market to Reach $3.7 Billion by 2015, According to New Report by Global Industry Analysts, Inc 3Health News:MicroRNAs make for safer cancer treatments 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 2Health News:New Joint Commission Consulting Service by NurseTesting Grows Fast as Staffing Agencies Seek Joint Commission Certification 3Health News:Speedy Care After Heart Attack Key to Survival 2
(Date:11/26/2014)... , November 26, 2014 Investor-Edge ... VVUS ), Horizon Pharma PLC (NASDAQ: ... and Johnson (NYSE: JNJ ), and Theravance Inc. ... companies can be accessed at: http://investor-edge.com/register . ... 4,758.25, up 0.07%, the Dow Jones Industrial Average edged 0.02% ...
(Date:11/26/2014)... SHANGHAI , Nov. 26, 2014  CARsgen, a ... (CAR-T) cell immunotherapy to treat a variety of cancers, ... led by BVCF, a China -based ... an immunotherapy company focused on the development of new ... collaboration with Shanghai Cancer Institute and Shanghai Renji Hospital, ...
(Date:11/26/2014)... N.C. , Nov. 25, 2014  At the ... Antonio this October, KaVo Kerr Group was ... Technology Expo, offering attendees the opportunity to see and ... well-respected key opinion leaders deliver lectures on the latest ... Group products include the new DEXIS CariVu Caries Detection ...
Breaking Medicine Technology:Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 2Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 3Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 4Pharma Stocks Highlight - VIVUS, Horizon Pharma, Endocyte, Johnson and Johnson, and Theravance 5CARsgen Completes Series A Financing 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 2KaVo Kerr Group Showcased in Pride Institute Technology Expo at ADA Annual Meeting 3
... , Jan. 29 EP Global Communications, Inc. ... ), the parent company of Exceptional Parent ( EP ) ... has joined the EPGL Advisory Board. Dr. DeFelice is one of the ... term "nutraceutical."  , "This addition to our team of experts will ...
... , PITTSBURGH , Jan. 29 ... subsidiary Mylan Pharmaceuticals Inc. received final approval from the U.S. ... Application (ANDA) for Polyethylene Glycol 3350 and Electrolytes for Oral ... , Polyethylene Glycol 3350 and Electrolytes for Oral Solution ...
Cached Medicine Technology:EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 2EP Global Communications, Inc. Welcomes Stephen DeFelice, MD, to Advisory Board 3Mylan Receives Approval for Generic Version of GoLytely(R) 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: